Advertisement

pp 1-47 | Cite as

Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR

  • Lídia Moreira Lima
  • Maria Letícia de Castro Barbosa
  • Daniel Nascimento do Amaral
  • Eliezer J. BarreiroEmail author
Chapter
  • 10 Downloads
Part of the Topics in Medicinal Chemistry book series

Abstract

Receptor tyrosine kinases (RTKs) are cell-surface proteins that trigger key cellular responses, such as survival, proliferation, differentiation, migration, and cell-cycle control. As increased activity, abundance, and/or cellular distribution of wild-type and mutant forms of RTKs is often associated with tumor establishment, growth, and progression, several drugs directed to clinically relevant RTKs have entered the pharmaceutical market since the beginning of the twenty-first century, representing innovative approaches for cancer treatment. The modulation strategies include small-molecule tyrosine kinase inhibitors (TKIs), targeting the ATP-binding site of the intracellular TK domain, and monoclonal antibodies directed to the extracellular domain, interfering with RTK activation and/or marking RTK-expressing cells for destruction by the immune system. Even though these drugs clearly represented an impressive breakthrough in the therapy of RTK-addicted tumors, resistance development and detection of refractory tumors have given rise to novel therapeutic challenges, pushing the drug discovery process forward. This chapter focuses particularly on the discussion of several case studies on the development of small-molecule tyrosine kinase inhibitors (TKIs) directed to EGFR, VEGFR, and PDGFR, clinically relevant RTKs, and the subset of advances in this field.

Keywords

Cancer Epidermal growth factor receptor (EGFR) Platelet-derived growth factor receptor (PDGFR) Receptor tyrosine kinases (RTKs) Tyrosine kinase inhibitors (TKIs) Vascular endothelial growth factor receptor (VEGFR) 

Notes

Compliance with Ethical Standards

Funding: This study was funded by INCT-INOFAR (CNPq#465.249/2014-0; FAPERJ#E-26/010.000090/2018)

Conflict of Interest: Authors (LML; MLCB; DNA; EJB) declare that they have no conflict of interest.

Ethical Approval: This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134.  https://doi.org/10.1016/j.cell.2010.06.011CrossRefGoogle Scholar
  2. 2.
    Wagner JP, Wolf-Yadlin A, Sevecka M et al (2013) Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal 6:ra58Google Scholar
  3. 3.
    Bayraktar UD, Bayraktar S, Rocha-Lima CM (2010) Molecular basis and management of gastrointestinal stromal tumours. World J Gastroenterol 16:2726–2734.  https://doi.org/10.3748/wjg.v16.i22.2726CrossRefGoogle Scholar
  4. 4.
    Guida T, Anaganti S, Provitera L et al (2007) Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res 13:3363–3369.  https://doi.org/10.1158/1078-0432.CCR-06-2667CrossRefGoogle Scholar
  5. 5.
    Liang L, Yan X-E, Yin Y, Yun C-H (2016) Structural and biochemical studies of the PDGFRA kinase domain. Biochem Biophys Res Commun 477:667–672.  https://doi.org/10.1016/j.bbrc.2016.06.117CrossRefGoogle Scholar
  6. 6.
    Shi L, Zhou J, Wu J et al (2016) Anti-angiogenic therapy: strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future prospect. Curr Med Chem 23:1000–1040Google Scholar
  7. 7.
    Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422–439.  https://doi.org/10.1016/j.tips.2015.04.005CrossRefGoogle Scholar
  8. 8.
    Vajpai N, Strauss A, Fendrich G et al (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283:18292–18302.  https://doi.org/10.1074/jbc.M801337200CrossRefGoogle Scholar
  9. 9.
    Dietrich J, Hulme C, Hurley LH (2010) The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg Med Chem 18:5738–5748.  https://doi.org/10.1016/j.bmc.2010.05.063CrossRefGoogle Scholar
  10. 10.
    Wu P, Nielsen TE, Clausen MH (2016) Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today 21:5–10.  https://doi.org/10.1016/j.drudis.2015.07.008CrossRefGoogle Scholar
  11. 11.
    Muralidhara C, Ramachandran A, Jain VK (2012) Abstract 3683: Crenolanib, a novel type I, mutant-specific inhibitor of class III receptor tyrosine kinases, preferentially binds to phosphorylated kinases. Cancer Res 72:3683–3683.  https://doi.org/10.1158/1538-7445.AM2012-3683CrossRefGoogle Scholar
  12. 12.
    Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12:17–28.  https://doi.org/10.1677/erc.1.01032CrossRefGoogle Scholar
  13. 13.
    Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65:1566–1584.  https://doi.org/10.1007/s00018-008-7440-8CrossRefGoogle Scholar
  14. 14.
    Tebbutt N, Pedersen MW, Johns TG (2013) Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 13:663–673.  https://doi.org/10.1038/nrc3559CrossRefGoogle Scholar
  15. 15.
    Zhang H, Berezov A, Wang Q et al (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Investig 117:2051–2058Google Scholar
  16. 16.
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655.  https://doi.org/10.1093/emboj/16.7.1647CrossRefGoogle Scholar
  17. 17.
    Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177–184Google Scholar
  18. 18.
    Nyati M, Morgan M, Feng F, Lawrence T (2006) Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6:876–885.  https://doi.org/10.1038/nrc1953CrossRefGoogle Scholar
  19. 19.
    Gao S, Mark K, Leslie K (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Investig 117:3846–3856.  https://doi.org/10.1172/JCI31871.3846CrossRefGoogle Scholar
  20. 20.
    Wang Q, Greene MI (2008) Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Investig 118:2389–2392.  https://doi.org/10.1172/JCI36260CrossRefGoogle Scholar
  21. 21.
    Hickey K, Grehan D, Reid IM et al (1994) Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 74:1693–1698.  https://doi.org/10.1002/1097-0142(19940915)74:6<1693::AID-CNCR2820740609>3.0.CO;2-#CrossRefGoogle Scholar
  22. 22.
    Liu B, Bernard B, Wu JH (2006) Impact of EGFR point mutations on the sensitivity to gefitinib : insights from comparative structural analyses and molecular dynamics simulations. Proteins Struct Funct Bioinf 65:331–346.  https://doi.org/10.1002/protCrossRefGoogle Scholar
  23. 23.
    Abella JV, Park M (2009) Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab 296:E973–E984.  https://doi.org/10.1152/ajpendo.90857.2008CrossRefGoogle Scholar
  24. 24.
    Meierjohann S, Hufnagel A, Wende E et al (2010) MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. Mol Cancer 9:201.  https://doi.org/10.1186/1476-4598-9-201CrossRefGoogle Scholar
  25. 25.
    Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3–9Google Scholar
  26. 26.
    Pines G, Huang PH, Zwang Y et al (2010) EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 29:5850–5860.  https://doi.org/10.1038/onc.2010.313CrossRefGoogle Scholar
  27. 27.
    Umekita Y, Ohi Y, Sagara Y, Yoshida H (2000) Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 89:484–487.  https://doi.org/10.1002/1097-0215(20001120)89:6<484::AID-IJC3>3.0.CO;2-SCrossRefGoogle Scholar
  28. 28.
    Chong CR, Jänne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19:1389–1400.  https://doi.org/10.1038/nm.3388CrossRefGoogle Scholar
  29. 29.
    Nawaz K, Webster RM (2016) The non-small-cell lung cancer drug market. Nat Rev Drug Discov 15:229–230.  https://doi.org/10.1038/nrd.2016.42CrossRefGoogle Scholar
  30. 30.
    Dienstmann R, De Dosso S, Felip E, Tabernero J (2012) Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 6:15–26Google Scholar
  31. 31.
    Moreira C, Kaklamani V (2010) Lapatinib and breast cancer: current indications and outlook for the future. Expert Rev Anticancer Ther 10:1171–1182.  https://doi.org/10.1586/era.10.113CrossRefGoogle Scholar
  32. 32.
    Ton GN, Banaszynski ME, Kolesar JM (2013) Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm 70:849–855Google Scholar
  33. 33.
    Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250.  https://doi.org/10.1016/S0163-7258(98)00045-XCrossRefGoogle Scholar
  34. 34.
    Ward WHJ, Cook PN, Slater AM et al (1994) Epidermal growth factor receptor tyrosine kinase. Biochem Pharmacol 48:659–666.  https://doi.org/10.1016/0006-2952(94)90042-6CrossRefGoogle Scholar
  35. 35.
    Fry DW, Kraker AJ, McMichael A et al (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093–1095.  https://doi.org/10.1126/science.8066447CrossRefGoogle Scholar
  36. 36.
    Rewcastle GW, Denny WA, Bridges AJ et al (1995) Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]-and 4-(phenylamino) quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 38:3482–3487Google Scholar
  37. 37.
    Wakeling AE, Barker AJ, Davies DH et al (1996) Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines A.E. Breast Cancer Res Treat 38:67–73Google Scholar
  38. 38.
    Denny WA, Rewcastle GW, Bridges AJ et al (1996) Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin Exp Pharmacol Physiol 23:424–427Google Scholar
  39. 39.
    Bridges AJ, Zhou H, Cody DR et al (1996) Tyrosine kinase inhibitors 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 39:267–276Google Scholar
  40. 40.
    Barreiro EJ, Kümmerle AE, Fraga CAM (2011) The methylation effect in medicinal chemistry. Chem Rev 111:5215–5246Google Scholar
  41. 41.
    Myers MR, Setzer N, Spada AP et al (1997) The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity. Bioorg Med Chem Lett 7:421–424Google Scholar
  42. 42.
    Myers MR, Setzer NN, Spada AP et al (1997) The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56(lck) and EGF-R tyorsine kinase activity. Bioorg Med Chem Lett 7:417–420.  https://doi.org/10.1016/S0960-894X(97)00034-6CrossRefGoogle Scholar
  43. 43.
    Barker AJ, Gibson KH, Grundy W et al (2001) Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911–1914.  https://doi.org/10.1016/S0960-894X(01)00344-4CrossRefGoogle Scholar
  44. 44.
    Böhm H-J, Banner D, Bendels S et al (2004) Fluorine in medicinal chemistry. Chembiochem 5:637–643.  https://doi.org/10.1002/cbic.200301023CrossRefGoogle Scholar
  45. 45.
    Gillis EP, Eastman KJ, Hill MD et al (2015) Applications of fluorine in medicinal chemistry. J Med Chem 58:8315–8359.  https://doi.org/10.1021/acs.jmedchem.5b00258CrossRefGoogle Scholar
  46. 46.
    Woodburn JR (1998) EGF receptor tyrosine kinase inhibitors as anti-cancer agents – pre-clinical and early clinical profile of ZD 1839. Cell Mol Biol Lett 3:348–349Google Scholar
  47. 47.
    Palmer BD, Trumpp-Kallmeyer S, Fry DW et al (1997) Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis. Biological evaluation, and modeling of the mode of binding. J Med Chem 40:1519–1529.  https://doi.org/10.1021/jm960789hCrossRefGoogle Scholar
  48. 48.
    Zheng J, Trafny EA, Knighton DR et al (1993) 2.2 angstrom refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr D Biol Crystallogr 49:362–365Google Scholar
  49. 49.
    Moyer JD, Barbacci EG, Iwata KK et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838–4848Google Scholar
  50. 50.
    Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265–46272.  https://doi.org/10.1074/jbc.M207135200CrossRefGoogle Scholar
  51. 51.
    Cohen MH (2003) FDA drug approval summary: Gefitinib (ZD1839) (Iressa(R)) tablets. Oncologist 8:303–306.  https://doi.org/10.1634/theoncologist.8-4-303CrossRefGoogle Scholar
  52. 52.
    Cohen M, Johnson J, Chen Y et al (2005) FDA drug approval summary: Erlotinib (Tarceva®) tablets. Oncologist 10:461–466Google Scholar
  53. 53.
    Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib – a novel targeted approach to treating cancer. Nat Rev Cancer 4:956–965.  https://doi.org/10.1038/nrc1506CrossRefGoogle Scholar
  54. 54.
    Juchum M, Gunther M, Laufer SA (2014) Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resist Updat 20:12–28.  https://doi.org/10.1016/j.drup.2015.05.002CrossRefGoogle Scholar
  55. 55.
    Ohashi K, Maruvka YE, Michor F, Pao W (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31:1070–1080Google Scholar
  56. 56.
    Fridlyand J, Simon RM, Walrath JC et al (2013) Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 12:743–755.  https://doi.org/10.1038/nrd4101CrossRefGoogle Scholar
  57. 57.
    Vargas AJ, Harris CC (2016) Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 16:525–537.  https://doi.org/10.1038/nrc.2016.56CrossRefGoogle Scholar
  58. 58.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139.  https://doi.org/10.1056/NEJMoa1109400CrossRefGoogle Scholar
  59. 59.
    Laufer S, Bajorath J (2015) Advancing the kinase field: new targets and second generation inhibitors. J Med Chem 58:1.  https://doi.org/10.1021/jm5018708CrossRefGoogle Scholar
  60. 60.
    Yun C, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070–2075.  https://doi.org/10.1073/pnas.0709662105CrossRefGoogle Scholar
  61. 61.
    Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 3:10–18Google Scholar
  62. 62.
    Oxnard GR, Arcila ME, Chmielecki J et al (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17:5530–5537.  https://doi.org/10.1158/1078-0432.CCR-10-2571CrossRefGoogle Scholar
  63. 63.
    Bikker JA, Brooijmans N, Wissner A, Mansour TS (2009) Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 52:1493–1509Google Scholar
  64. 64.
    Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726.  https://doi.org/10.1038/nrc3599CrossRefGoogle Scholar
  65. 65.
    Godin-Heymann N, Ulkus L, Brannigan BW et al (2008) The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 7:874–879.  https://doi.org/10.1158/1535-7163.MCT-07-2387CrossRefGoogle Scholar
  66. 66.
    Gajiwala KS, Feng J, Ferre R et al (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21:209–219.  https://doi.org/10.1016/j.str.2012.11.014CrossRefGoogle Scholar
  67. 67.
    Doebele RC, Oton AB, Peled N et al (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1–12.  https://doi.org/10.1016/j.lungcan.2009.12.009CrossRefGoogle Scholar
  68. 68.
    Zhou W, Ercan D, Chen L et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070–1074.  https://doi.org/10.1038/nature08622CrossRefGoogle Scholar
  69. 69.
    Kwak EL, Sordella R, Bell DW et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665–7670.  https://doi.org/10.1073/pnas.0502860102CrossRefGoogle Scholar
  70. 70.
    Liu Q, Sabnis Y, Zhao Z et al (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 20:146–159.  https://doi.org/10.1016/j.chembiol.2012.12.006CrossRefGoogle Scholar
  71. 71.
    Mah R, Thomas JR, Shafer CM (2014) Drug discovery considerations in the development of covalent inhibitors. Bioorg Med Chem Lett 24:33–39Google Scholar
  72. 72.
    Singh J, Petter RC, Baillie TA, Whitty A (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307–317.  https://doi.org/10.1038/nrd3410CrossRefGoogle Scholar
  73. 73.
    Barf T, Kaptein A (2012) Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem 55:6243–6262.  https://doi.org/10.1021/jm3003203CrossRefGoogle Scholar
  74. 74.
    Kalgutkar AS, Dalvie DK (2012) Drug discovery for a new generation of covalent drugs. Expert Opin Drug Discovery 7:561–581.  https://doi.org/10.1517/17460441.2012.688744CrossRefGoogle Scholar
  75. 75.
    Levitzki A (2013) Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol 53:161–185.  https://doi.org/10.1146/annurev-pharmtox-011112-140341CrossRefGoogle Scholar
  76. 76.
    Singh J, Dobrusin EM, Fry DW et al (1997) Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J Med Chem 40:1130–1135.  https://doi.org/10.1021/jm960380sCrossRefGoogle Scholar
  77. 77.
    Fry DW, Bridges AJ, Denny WA et al (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A 95:12022–12027.  https://doi.org/10.1073/pnas.95.20.12022CrossRefGoogle Scholar
  78. 78.
    Smaill JB, Palmer BD, Rewcastle GW et al (1999) 4-(Phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 42:1803–1815Google Scholar
  79. 79.
    Smaill JB, Rewcastle GW, Loo JA et al (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4- (phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 43:1380–1397.  https://doi.org/10.1021/jm990482tCrossRefGoogle Scholar
  80. 80.
    Williams R (2008) Discontinued drugs in 2006: oncology drugs. Expert Opin Investig Drugs 17:269–283.  https://doi.org/10.1517/13543784.17.3.269CrossRefGoogle Scholar
  81. 81.
    Tsou HR, Mamuya N, Johnson BD et al (2001) 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumour activity. J Med Chem 44:2719–2734.  https://doi.org/10.1021/jm0005555CrossRefGoogle Scholar
  82. 82.
    Carmi C, Lodola A, Rivara S et al (2011) Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. Mini Rev Med Chem 11:1019–1030.  https://doi.org/10.2174/138955711797247725CrossRefGoogle Scholar
  83. 83.
    Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction – a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448–457.  https://doi.org/10.1038/ncponc0558CrossRefGoogle Scholar
  84. 84.
    Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–4711.  https://doi.org/10.1038/onc.2008.109CrossRefGoogle Scholar
  85. 85.
    Eskens FALM, Mom CH, Planting AST et al (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80–85.  https://doi.org/10.1038/sj.bjc.6604108CrossRefGoogle Scholar
  86. 86.
    Fiala O, Pesek M, Finek J et al (2013) Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 60:26–32.  https://doi.org/10.4149/neo_2013_004CrossRefGoogle Scholar
  87. 87.
    Giordano P, Manzo A, Montanino A et al (2016) Afatinib: an overview of its clinical development in non-small-cell lung cancer and other tumours. Crit Rev Oncol Hematol 97:143–151Google Scholar
  88. 88.
    Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342–350.  https://doi.org/10.1124/jpet.112.197756CrossRefGoogle Scholar
  89. 89.
    Miller VA, Hirsh V, Cadranel J et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13:528–538.  https://doi.org/10.1016/S1470-2045(12)70087-6CrossRefGoogle Scholar
  90. 90.
    Sanderson K (2013) Irreversible kinase inhibitors gain traction. Nat Rev Drug Discov 12:649–651.  https://doi.org/10.1038/nrd4103CrossRefGoogle Scholar
  91. 91.
    Cross DAE, Ashton SE, Ghiorghiu S et al (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046–1061.  https://doi.org/10.1158/2159-8290.CD-14-0337CrossRefGoogle Scholar
  92. 92.
    Smit EF, Baas P (2015) Lung cancer in 2015: bypassing checkpoints, overcoming resistance, and honing in on new targets. Nat Rev Clin Oncol 13:75–76.  https://doi.org/10.1038/nrclinonc.2015.223CrossRefGoogle Scholar
  93. 93.
    Thress KS, Paweletz CP, Felip E et al (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21:560–562.  https://doi.org/10.1038/nm.3854CrossRefGoogle Scholar
  94. 94.
    Hanan EJ, Eigenbrot C, Bryan MC et al (2014) Discovery of selective and non-covalent diaminopyrimidine based inhibitors of EGFR containing the T790M resistance mutation. J Med Chem 57:10176.  https://doi.org/10.1021/jm501578nCrossRefGoogle Scholar
  95. 95.
    Heald R, Bowman KK, Bryan MC et al (2015) Noncovalent mutant selective epidermal growth factor receptor inhibitors: a lead optimization case study. J Med Chem 58:8877–8895.  https://doi.org/10.1021/acs.jmedchem.5b01412CrossRefGoogle Scholar
  96. 96.
    Jia Y, Yun C-H, Park E et al (2016) Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534:129–132.  https://doi.org/10.1038/nature17960CrossRefGoogle Scholar
  97. 97.
    Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19:2003–2012.  https://doi.org/10.1016/j.cellsig.2007.05.013CrossRefGoogle Scholar
  98. 98.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676.  https://doi.org/10.1038/nm0603-669CrossRefGoogle Scholar
  99. 99.
    Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-Angiogenic therapies. Genes Cancer 2:1097–1105.  https://doi.org/10.1177/1947601911423031CrossRefGoogle Scholar
  100. 100.
    Takahashi S (2011) Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumour therapy. Biol Pharm Bull 34:1785–1788.  https://doi.org/10.1248/bpb.34.1785CrossRefGoogle Scholar
  101. 101.
    Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464–478.  https://doi.org/10.1038/nrm2183CrossRefGoogle Scholar
  102. 102.
    Bergers G, Benjamin LE (2003) Tumourigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410.  https://doi.org/10.1038/nrc1093CrossRefGoogle Scholar
  103. 103.
    Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936.  https://doi.org/10.1038/nature04478CrossRefGoogle Scholar
  104. 104.
    Hoeben A, Landuyt B, Highley MS et al (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580.  https://doi.org/10.1124/pr.56.4.3.549CrossRefGoogle Scholar
  105. 105.
    Schenone S, Bondavalli F, Botta M (2007) Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem 14:2495–2516.  https://doi.org/10.2174/092986707782023622CrossRefGoogle Scholar
  106. 106.
    Moreira IS, Fernandes PA, Ramos MJ (2007) Vascular endothelial growth factor (VEGF) inhibition – a critical review. Anti Cancer Agents Med Chem 7:223–245Google Scholar
  107. 107.
    Lee SH, Jeong D, Han Y-S, Baek MJ (2015) Pivotal role of vascular endothelial growth factor pathway in tumour angiogenesis. Ann Surg Treat Res 89:1–8.  https://doi.org/10.4174/astr.2015.89.1.1CrossRefGoogle Scholar
  108. 108.
    Holmes DIR, Zachary I (2005) The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 6:209.  https://doi.org/10.1186/gb-2005-6-2-209CrossRefGoogle Scholar
  109. 109.
    Terman BI, Carrion ME, Kovacs E et al (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677–1683.  https://doi.org/10.1383/surg.23.2.37.60352CrossRefGoogle Scholar
  110. 110.
    Dougher-Vermazen M, Hulmes JD, Böhlen P, Terman BI (1994) Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 205:728–738Google Scholar
  111. 111.
    Fuh G, Li B, Crowley C et al (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273:11197–11204.  https://doi.org/10.1074/jbc.273.18.11197CrossRefGoogle Scholar
  112. 112.
    Roskoski R (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375:287–291Google Scholar
  113. 113.
    Simons M, Gordon E, Claesson-Welsh L (2016) Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 17:611–625.  https://doi.org/10.1038/nrm.2016.87CrossRefGoogle Scholar
  114. 114.
    Youssoufian H, Hicklin DJ, Rowinsky EK (2007) Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 13:5544s–5548s.  https://doi.org/10.1158/1078-0432.CCR-07-1107CrossRefGoogle Scholar
  115. 115.
    Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72:1909–1914.  https://doi.org/10.1158/0008-5472.CAN-11-3406CrossRefGoogle Scholar
  116. 116.
    Xu D, Wang T-L, Sun L-P, You Q-D (2011) Recent progress of small molecular VEGFR inhibitors as anticancer agents. Mini Rev Med Chem 11:18–31.  https://doi.org/10.2174/138955711793564015CrossRefGoogle Scholar
  117. 117.
    Zhang J, Shan Y, Pan X, He L (2011) Recent advances in antiangiogenic agents with VEGFR as target. Mini Rev Med Chem 11:920–946.  https://doi.org/10.2174/138955711797068355CrossRefGoogle Scholar
  118. 118.
    Sharma PS, Sharma R, Tyagi T (2011) VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets 11:624–653Google Scholar
  119. 119.
    Zhang C, Tan C, Ding H et al (2012) Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials. Curr Pharm Des 18:2921–2935.  https://doi.org/10.2174/138161212800672732CrossRefGoogle Scholar
  120. 120.
    Matsui J, Yamamoto Y, Funahashi Y et al (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumour activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664–671.  https://doi.org/10.1002/ijc.23131CrossRefGoogle Scholar
  121. 121.
    Okamoto K, Ikemori-Kawada M, Jestel A et al (2014) Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett 6:89–94.  https://doi.org/10.1021/ml500394mCrossRefGoogle Scholar
  122. 122.
    Roskoski R (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26–48.  https://doi.org/10.1016/j.phrs.2015.10.021CrossRefGoogle Scholar
  123. 123.
    Boss DS, Glen H, Beijnen JH et al (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106:1598–1604.  https://doi.org/10.1038/bjc.2012.154CrossRefGoogle Scholar
  124. 124.
    Inoue K, Mizuo H, Kawaguchi S et al (2014) Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase. Drug Metab Dispos 42:1326–1333.  https://doi.org/10.1124/dmd.114.058073CrossRefGoogle Scholar
  125. 125.
    Shumaker R, Aluri J, Fan J et al (2015) Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants. Clin Pharmacol Drug Dev 4:155–160.  https://doi.org/10.1002/cpdd.140CrossRefGoogle Scholar
  126. 126.
    Shumaker RC, Aluri J, Fan J et al (2014) Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig 34:651–659.  https://doi.org/10.1007/s40261-014-0217-yCrossRefGoogle Scholar
  127. 127.
    Matsui J, Funahashi Y, Uenaka T et al (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:5459–5465.  https://doi.org/10.1158/1078-0432.CCR-07-5270CrossRefGoogle Scholar
  128. 128.
    Scott LJ (2015) Lenvatinib: first global approval. Drugs 75:553–560Google Scholar
  129. 129.
    Tohyama O, Matsui J, Kodama K et al (2014) Antitumour activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid Cancer models. J Thyroid Res 2014:1–13.  https://doi.org/10.1155/2014/638747. ID 638747CrossRefGoogle Scholar
  130. 130.
    Frampton JE (2016) Lenvatinib: a review in refractory thyroid Cancer. Target Oncol 11:115–122Google Scholar
  131. 131.
    Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid Cancer. N Engl J Med 372:621–630.  https://doi.org/10.1056/NEJMoa1406470CrossRefGoogle Scholar
  132. 132.
    Cao Y (2013) Multifarious functions of PDGFs and PDGFRs in tumour growth and metastasis. Trends Mol Med 19:460–473.  https://doi.org/10.1016/j.molmed.2013.05.002CrossRefGoogle Scholar
  133. 133.
    Heldin C-H (2013) Targeting the PDGF signaling pathway in tumour treatment. Cell Commun Signal 11:97.  https://doi.org/10.1186/1478-811X-11-97CrossRefGoogle Scholar
  134. 134.
    Lewis NL, Lewis LD, Eder JP et al (2009) Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 27:5262–5269.  https://doi.org/10.1200/JCO.2009.21.8487CrossRefGoogle Scholar
  135. 135.
    Chen P-HH, Chen X, He X (2013) Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta 1834:2176–2186.  https://doi.org/10.1016/j.bbapap.2012.10.015CrossRefGoogle Scholar
  136. 136.
    Michael M, Vlahovic G, Khamly K et al (2010) Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. Br J Cancer 103:1554–1561.  https://doi.org/10.1038/sj.bjc.6605941CrossRefGoogle Scholar
  137. 137.
    Suzuki S, Heldin C, Heuchel RL (2007) Platelet-derived growth factor receptor-beta, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma. BMC Cancer 7:224.  https://doi.org/10.1186/1471-2407-7-224CrossRefGoogle Scholar
  138. 138.
    Estevez-Garcia P, Castaño A, Martin AC et al (2012) PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer 12:514.  https://doi.org/10.1186/1471-2407-12-514CrossRefGoogle Scholar
  139. 139.
    Wehler T, Frerichs K, Graf C et al (2008) PDGFRα/β expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep 19:697–704.  https://doi.org/10.3892/or.19.3.697CrossRefGoogle Scholar
  140. 140.
    Paulsson J, Sjoblom T, Micke P et al (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334–341.  https://doi.org/10.2353/ajpath.2009.081030CrossRefGoogle Scholar
  141. 141.
    Tefferi A (2009) Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med 13:215–237.  https://doi.org/10.1111/j.1582-4934.2008.00559.xCrossRefGoogle Scholar
  142. 142.
    Golub TR, Barker GF, Lovett M, Gary Gilliland D (1994) Fusion of PDGF receptor B to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307–316.  https://doi.org/10.1016/0092-8674(94)90322-0CrossRefGoogle Scholar
  143. 143.
    Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214Google Scholar
  144. 144.
    Lierman E, Michaux L, Beullens E et al (2009) FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 23:845–851.  https://doi.org/10.1038/leu.2009.2CrossRefGoogle Scholar
  145. 145.
    Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357–5364.  https://doi.org/10.1200/JCO.2005.14.068CrossRefGoogle Scholar
  146. 146.
    Debiec-Rychter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 40:689–695.  https://doi.org/10.1016/j.ejca.2003.11.025CrossRefGoogle Scholar
  147. 147.
    Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumours. Science 299:708–711Google Scholar
  148. 148.
    Boyar MS, Taub RN (2007) New strategies for treating GIST when imatinib fails. Cancer Investig 25:328–335.  https://doi.org/10.1080/07357900701206273CrossRefGoogle Scholar
  149. 149.
    Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 21:4342–4349.  https://doi.org/10.1200/JCO.2003.04.190CrossRefGoogle Scholar
  150. 150.
    Hirota S, Ohashi A, Nishida T et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumours. Gastroenterology 125:660–667.  https://doi.org/10.1016/S0016-5085(03)01046-1CrossRefGoogle Scholar
  151. 151.
    Kim EJ, Zalupski MM (2011) Systemic therapy for advanced gastrointestinal stromal tumours: beyond imatinib. J Surg Oncol 104:901–906.  https://doi.org/10.1002/jso.21872CrossRefGoogle Scholar
  152. 152.
    Wang P, Song L, Ge H et al (2014) Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumour growth in vivo. Onco Targets Ther 7:1761–1768Google Scholar
  153. 153.
    Gambacorti-Passerini CB, Gunby RH, Piazza R et al (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4:75–85.  https://doi.org/10.1016/S1470-2045(03)00979-3CrossRefGoogle Scholar
  154. 154.
    Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566.  https://doi.org/10.1038/nm0596-561CrossRefGoogle Scholar
  155. 155.
    Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361–370.  https://doi.org/10.1038/nrc1360CrossRefGoogle Scholar
  156. 156.
    von Bubnoff N, Gorantla SP, Engh RA et al (2011) The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 30:933–943.  https://doi.org/10.1038/onc.2010.476CrossRefGoogle Scholar
  157. 157.
    Weisberg E, Wright RD, Jiang J et al (2006) Effects of PKC412, Nilotinib, and Imatinib against GIST-associated PDGFRA mutants with differential Imatinib sensitivity. Gastroenterology 131:1734–1742.  https://doi.org/10.1053/j.gastro.2006.09.017CrossRefGoogle Scholar
  158. 158.
    Heinrich MC, Griffith D, McKinley A et al (2012) Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumours. Clin Cancer Res 18:4375–4384.  https://doi.org/10.1158/1078-0432.CCR-12-0625CrossRefGoogle Scholar
  159. 159.
    Smith CC, Lasater EA, Lin KC et al (2014) Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A 111:5319–5324.  https://doi.org/10.1073/pnas.1320661111CrossRefGoogle Scholar
  160. 160.
    Roberts WG, Whalen PM, Soderstrom E et al (2005) Antiangiogenic and antitumour activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 65:957–966Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Lídia Moreira Lima
    • 1
  • Maria Letícia de Castro Barbosa
    • 1
  • Daniel Nascimento do Amaral
    • 1
  • Eliezer J. Barreiro
    • 1
    Email author
  1. 1.Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de JaneiroRio de JaneiroBrazil

Personalised recommendations